Get started
Author

Linyu Wu

Observed names: L. Wu, Liang-Cheng Wu, Longwang Wu
Observed institutions: Central South University, Army Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College, Fudan University, Hunan Cancer Hospital, Beijing Ditan Hospital
ORCID: 0009-0002-0733-8904
Observed ORCID: 0009-0002-0733-8904
OpenAlex ID: A5115597478
PL02.04 Phase 3 Study of Ivonescimab (AK112) vs. Pembrolizumab as First-line Treatment for PD-L1-positive Advanced NSCLC: Primary Analysis of HARMONi-2
2024 · C. Zhou, J. Chen, et al. · Journal of Thoracic Oncology · 25
PDF
Corneal confocal microscopy as a non-invasive test to assess diabetic peripheral neuropathy
2017 · Qian Xiong, Bin Lu, et al. · Diabetes Research and Clinical Practice · 19
OA14.03 Garsorasib in KRAS G12C-Mutated Non-Small-Cell Lung Cancer: Updated Results from a Phase 2 Study
2024 · Z. Li, S. Lu, et al. · Journal of Thoracic Oncology · 4
Target intraocular pressure level in patients with different stages of low tension glaucoma
2025 · E.A. Egorov, A.V. Kuroyedov, et al. · Russian Journal of Clinical Ophthalmology · 2
644P Tifcemalimab combined with toripalimab and docetaxel as 2nd line treatment for immunotherapy-treated squamous cell non-small cell lung cancer (Sq-NSCLC) patients: A phase Ib/II study
2024 · D. Lv, Y. Zhang, et al. · Annals of Oncology · 2
PDF
1310P SHR-A1921: A trophoblast cell-surface antigen 2 (TROP-2) targeted antibody-drug conjugate (ADC) for the treatment of advanced NSCLC
2024 · J. Wang, L. Wu, et al. · Annals of Oncology · 1
PDF
EP.12.06 Brilliant First Analysis: A Real-World Study of Characteristics and Safety About Brigatinib as First-Line for Chinese Patients With ALK+ NSCLC
2025 · L. Wang, F. Zhou, et al. · Journal of Thoracic Oncology
Supplementary Methods S1 from Intestinal Subtype as a Biomarker of Response to Neoadjuvant Immunochemotherapy in Locally Advanced Gastric Adenocarcinoma: Insights from a Prospective Phase II Trial
2025 · Lei Wang, Mengting Sun, et al.
Data from Intestinal Subtype as a Biomarker of Response to Neoadjuvant Immunochemotherapy in Locally Advanced Gastric Adenocarcinoma: Insights from a Prospective Phase II Trial
2025 · Lei Wang, Mengting Sun, et al.
Supplementary Figure S2 from Intestinal Subtype as a Biomarker of Response to Neoadjuvant Immunochemotherapy in Locally Advanced Gastric Adenocarcinoma: Insights from a Prospective Phase II Trial
2025 · Lei Wang, Mengting Sun, et al.
Supplementary Figure S4 from Intestinal Subtype as a Biomarker of Response to Neoadjuvant Immunochemotherapy in Locally Advanced Gastric Adenocarcinoma: Insights from a Prospective Phase II Trial
2025 · Lei Wang, Mengting Sun, et al.
Supplementary Tables S5-S8 from Intestinal Subtype as a Biomarker of Response to Neoadjuvant Immunochemotherapy in Locally Advanced Gastric Adenocarcinoma: Insights from a Prospective Phase II Trial
2025 · Lei Wang, Mengting Sun, et al.
Supplementary Data S1 from Intestinal Subtype as a Biomarker of Response to Neoadjuvant Immunochemotherapy in Locally Advanced Gastric Adenocarcinoma: Insights from a Prospective Phase II Trial
2025 · Lei Wang, Mengting Sun, et al.
Supplementary Table S3 from Intestinal Subtype as a Biomarker of Response to Neoadjuvant Immunochemotherapy in Locally Advanced Gastric Adenocarcinoma: Insights from a Prospective Phase II Trial
2025 · Lei Wang, Mengting Sun, et al.
Supplementary Table S4 from Intestinal Subtype as a Biomarker of Response to Neoadjuvant Immunochemotherapy in Locally Advanced Gastric Adenocarcinoma: Insights from a Prospective Phase II Trial
2025 · Lei Wang, Mengting Sun, et al.
Supplementary Figure S1 from Intestinal Subtype as a Biomarker of Response to Neoadjuvant Immunochemotherapy in Locally Advanced Gastric Adenocarcinoma: Insights from a Prospective Phase II Trial
2025 · Lei Wang, Mengting Sun, et al.
Supplementary Table S9 from Intestinal Subtype as a Biomarker of Response to Neoadjuvant Immunochemotherapy in Locally Advanced Gastric Adenocarcinoma: Insights from a Prospective Phase II Trial
2025 · Lei Wang, Mengting Sun, et al.
Supplementary Figure S3 from Intestinal Subtype as a Biomarker of Response to Neoadjuvant Immunochemotherapy in Locally Advanced Gastric Adenocarcinoma: Insights from a Prospective Phase II Trial
2025 · Lei Wang, Mengting Sun, et al.
Supplementary Table S2 from Intestinal Subtype as a Biomarker of Response to Neoadjuvant Immunochemotherapy in Locally Advanced Gastric Adenocarcinoma: Insights from a Prospective Phase II Trial
2025 · Lei Wang, Mengting Sun, et al.
Supplementary Table S1 from Intestinal Subtype as a Biomarker of Response to Neoadjuvant Immunochemotherapy in Locally Advanced Gastric Adenocarcinoma: Insights from a Prospective Phase II Trial
2025 · Lei Wang, Mengting Sun, et al.
Identification of SPP1 as a Core Driver of Fuchs' Endothelial Corneal Dystrophy and its Upstream ceRNA Regulatory Network through Integrated Bioinformatics and Time-Resolved Single-Cell Transcriptomic Validation
2025 · Fuji Deng, Zhixiang Yan, et al. · SSRN Electronic Journal
388P RENI-1 efficacy and safety of niraparib as first-line maintenance therapy in newly diagnosed ovarian cancer: A prospective, multicenter real-world study, updated in 24-month follow-up
2024 · Z. Zheng, J. Zuo, et al. · Annals of Oncology
PDF
PP-070 Screening of zinc finger genes differentially expressed in L02 cells transfected with hHGF
2008 · L. Wu, J.Q. Zhang, et al. · International Journal of Infectious Diseases
PDF
Works count: 23
Citation count: 53
H-index: 3
I10-index: 2
Year
Topic
Type